GOLDMAN SACHS GROUP INC - IOVANCE BIOTHERAPEUTICS INC ownership

IOVANCE BIOTHERAPEUTICS INC's ticker is IOVA and the CUSIP is 462260100. A total of 221 filers reported holding IOVANCE BIOTHERAPEUTICS INC in Q2 2023. The put-call ratio across all filers is 0.65 and the average weighting 0.1%.

Quarter-by-quarter ownership
GOLDMAN SACHS GROUP INC ownership history of IOVANCE BIOTHERAPEUTICS INC
ValueSharesWeighting
Q2 2024$21,026,708
-62.5%
2,621,784
-30.7%
0.00%
-60.0%
Q1 2024$56,057,583
+87.3%
3,782,563
+2.7%
0.01%
+66.7%
Q4 2023$29,931,082
+74.8%
3,681,560
-2.2%
0.01%
+50.0%
Q3 2023$17,124,553
-31.2%
3,763,638
+6.5%
0.00%
-20.0%
Q2 2023$24,888,280
+3.6%
3,535,267
-10.1%
0.01%
-16.7%
Q1 2023$24,030,532
+3.2%
3,932,984
+8.0%
0.01%0.0%
Q4 2022$23,279,185
+81034.8%
3,643,065
+21.6%
0.01%
-14.3%
Q3 2022$28,692
+33.1%
2,994,979
+53.4%
0.01%
+40.0%
Q2 2022$21,554
-99.8%
1,952,346
+225.7%
0.01%
+150.0%
Q1 2022$9,979,000
-65.0%
599,371
-59.9%
0.00%
-60.0%
Q4 2021$28,525,000
-7.8%
1,494,204
+19.1%
0.01%
-28.6%
Q3 2021$30,951,000
-30.9%
1,255,100
-27.1%
0.01%
-30.0%
Q2 2021$44,822,000
-26.2%
1,722,578
-10.2%
0.01%
-33.3%
Q1 2021$60,709,000
+75.4%
1,917,509
+157.1%
0.02%
+66.7%
Q4 2020$34,604,000
+28.3%
745,770
-9.0%
0.01%
+12.5%
Q3 2020$26,967,000
-31.4%
819,151
-42.8%
0.01%
-33.3%
Q2 2020$39,290,000
+16.3%
1,431,325
+26.8%
0.01%0.0%
Q1 2020$33,785,000
-0.8%
1,128,608
-8.2%
0.01%
+50.0%
Q4 2019$34,044,000
+78.5%
1,229,954
+17.4%
0.01%
+33.3%
Q3 2019$19,070,000
+35.6%
1,047,792
+82.7%
0.01%
+50.0%
Q2 2019$14,060,000
+238.1%
573,378
+31.1%
0.00%
+300.0%
Q1 2019$4,158,000
-32.2%
437,263
-36.9%
0.00%
-50.0%
Q4 2018$6,136,000
+183.3%
693,301
+260.1%
0.00%
+100.0%
Q3 2018$2,166,000
+99.1%
192,536
+126.4%
0.00%
Q2 2018$1,088,000
-32.1%
85,037
-10.3%
0.00%
Q1 2018$1,602,000
+215.4%
94,793
+49.5%
0.00%
Q4 2017$508,000
-70.6%
63,414
-71.5%
0.00%
Q3 2017$1,727,000
+9.7%
222,784
+4.0%
0.00%
Q2 2017$1,575,000214,2110.00%
Other shareholders
IOVANCE BIOTHERAPEUTICS INC shareholders Q2 2023
NameSharesValueWeighting ↓
ACUTA CAPITAL PARTNERS, LLC 3,019,201$26,720,00020.38%
Broadfin Capital, LLC 5,951,153$52,668,0006.92%
GREAT POINT PARTNERS LLC 5,567,348$49,271,0006.23%
Avoro Capital Advisors LLC 10,261,039$90,810,0005.43%
FRAZIER MANAGEMENT LLC 2,188,331$19,367,0005.00%
Prosight Management, LP 1,062,500$9,403,0004.85%
Perceptive Advisors 12,241,111$108,333,0004.12%
Ghost Tree Capital, LLC 1,000,000$8,850,0003.21%
QVT Financial LP 1,021,361$8,696,0002.84%
Vivo Capital, LLC 1,600,000$14,160,0001.81%
View complete list of IOVANCE BIOTHERAPEUTICS INC shareholders